Pharmaceutical companies into the drug store market share "cake"
It is understood that related to sideline the past few years into the Pharmaceutical companies Have reaped good results: Wong Lo Kat herbal tea granules, Guangdong Pharmaceutical Sell Is over 100 million yuan, annual sales of Wong Lo Kat drinks are also more than 200 million yuan; short period of 3 years Yunnanbaiyao Toothpaste toothpaste industry has done a 300 million yuan in the market. One of the pharmaceutical companies into the Japanese leader said ambitious: the next few years, drug and cosmetic products will be able to sell billions of dollars to achieve the goal, this is based on China's rapid economic development and related industries gushing-type measure of growth. September 2008, Kunming flame Pharmaceutical (Group) Co., Ltd. o ...
Price adjustment be spotted crux of vigorous pharmaceutical companies - pharmaceutical companies - pharmaceutical industries
The current environment, some pharmaceutical companies to enhance the quality of the driving force for the lack of consciousness. First of all, talk about it from drug prices. For the suppression Pharmacy Price, NDRC launched 25 times in recent years, a wide range of price adjustment, but "your doctor" issue has not been significantly alleviated, there is still good value many of the early termination of the life cycle of drugs on the market some of the life-saving cheap old Drugs not a trace repeatedly appeared in press. Some pharmaceutical companies produce drugs, especially low-cost drugs, low-limit feeding, cutting corners, shoddy materials.
Empathy lethal drugs on transnational pharmaceutical companies - multinational, pharmaceutical companies - pharmaceutical industry
The past 10 years, a number of key therapeutic areas to the multinational pharmaceutical industry giants bring huge profits. However, ten years, Hexi east of the river, as the business environment changes, they are giving up these areas of research and development activities, move on to more profitable diseases such as cancer and anti-dementia drug treatment. It also can adapt to growing risk aversion of regulators.